key: cord-0875586-18p0fs2m
authors: Buehler, Philipp K.; Zinkernagel, Annelies S.; Hofmaenner, Daniel A.; Wendel Garcia, Pedro David; Acevedo, Claudio T.; Gómez-Mejia, Alejandro; Shambat, Srikanth Mairpady; Andreoni, Federica; Maibach, Martina A.; Bartussek, Jan; Hilty, Matthias P.; Frey, Pascal M.; Schuepbach, Reto A.; Brugger, Silvio D.
title: Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients
date: 2021-03-14
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100229
sha: d8eab8d23468d0a883daf162ea33611d1ba77815
doc_id: 875586
cord_uid: 18p0fs2m

The impact of secondary bacterial infections (superinfections) in COVID-19 is not well understood. In this prospective, monocentric cohort study we aim to investigate the impact of superinfections in COVID-19 patients with acute respiratory distress syndrome. Patients are assessed for concomitant microbial infections by longitudinal analysis of tracheobronchial secretions, bronchoalveolar lavages and blood cultures. In 45 critically ill patients, we identify 19 patients with superinfections (42.2%). Superinfections are detected on day 10 after intensive care admission. The proportion of participants alive and off invasive mechanical ventilation at study day 28 (ventilator-free days (VFDs) at 28 days) is substantially lower in patients with superinfection (subhazard ratio 0.37, 95%-CI 0.15-0.90, p=0.028). Patients with pulmonary superinfections have a higher incidence of bacteraemia, virus reactivations, yeast colonization, and required intensive care treatment for a longer time. Superinfections are frequent and associated with reduced VFDs at 28 days despite a high rate of empirical antibiotic therapy.

The impact of secondary bacterial infections (superinfections) in COVID-19 is 3 not well understood. In this prospective, monocentric cohort study we aim to 4 investigate the impact of superinfections in COVID-19 patients with acute 5 respiratory distress syndrome. Patients are assessed for concomitant 6 microbial infections by longitudinal analysis of tracheobronchial secretions, 7 bronchoalveolar lavages and blood cultures. In 45 critically ill patients, we 8 identify 19 patients with superinfections (42.2%). Superinfections are detected 9 on day 10 after intensive care admission. The proportion of participants alive 10 and off invasive mechanical ventilation at study day 28 (ventilator-free days 11 (VFDs) at 28 days) is substantially lower in patients with superinfection 12 (subhazard ratio 0.37, 95%-CI 0.15-0.90, p=0.028). Patients with pulmonary 13 superinfections have a higher incidence of bacteraemia, virus reactivations, 14 yeast colonization, and required intensive care treatment for a longer time. 15 Superinfections are frequent and associated with reduced VFDs at 28 days 16 despite a high rate of empirical antibiotic therapy. 28 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved as 29 the most relevant pandemic of modern history, challenging health care systems all over 30 the world. The clinical characteristics of coronavirus disease 19 (COVID-19) patients 31 have been thoroughly described in recent studies 1-5 . The triggers for acute respiratory 32 distress syndrome (ARDS) in COVID-19 are virus-initiated, subsequently leading to 33 inflammation-mediated lung damage and endotheliitis 5 . Although primarily a viral 34 disease, antibiotics are empirically used in over 70% of cases in addition to 35 experimental antiviral and immunomodulatory treatments 1, 4-7 . Secondary bacterial 36 and/or fungal infections are a well-described phenomenon in viral illnesses such as 37 influenza and are associated with increased morbidity and mortality in viral ARDS as 38 illustrated during previous pandemics 8 . Secondary bacterial infections are typically 39 referred to as superinfections whereas co-infection is mainly used to describe 40 simultaneous virus infection. Both, co-and superinfection have been described in 41 COVID-19 patients 6, 9 . Data regarding bacterial superinfections in COVID-19 42 pneumonia are limited and still emerging 10, 11 . A recent systematic review has 43 concluded that the rate of bacterial/fungal superinfections is low, arguing against the 44 frequent use of broad-spectrum antimicrobials in patients with COVID-19 11, 12 . 45 However, COVID-19 associated pulmonary aspergillosis (CAPA) has been reported in 46 several cohorts of critically ill patients 13, 14 total of 152 blood culture pairs ( Table 2) . 107 The detection time points of pulmonary relevant and non-relevant microorganisms are 108 depicted in Figure 1 and S2, respectively. On average, relevant pulmonary pathogens 109 were detected on day ten after ICU admission and reflect the hospital-acquired 110 pneumonia (HAP) / ventilator-associated pneumonia (VAP) spectrum ( Figure 1A ). Non-111 relevant pulmonary pathogens 22 were detected on average on day three post ICU 112 admission ( Figure S2 ). The most frequently isolated bacteria per patient were: Figure S2 . Table 2) . 149 Longitudinal laboratory inflammation parameters (leukocytes, CRP, PCT and 150 Neutrophil/Lymphocyte ratio) for days 1-16 are shown in Figure S3 and Table S1 . Only Figure S3 and Table S1 . Herpes simplex virus type 2(HSV-2) (PCR in blood) 0 (0%) 0 (0%) Human herpesvirus 6 (HHV-6) (PCR in blood) 0 (0%) 2 (22.2%)

Cytomegalovirus (CMV) (PCR in blood) 1 (50%) 0 (0%) Epstein-Barr virus (EBV) (PCR in blood) 1 (50%) 1 (11.1%) The data are presented as median (95%CI of median) or number and (percentage %). The two groups were compared using Chi-Square Test/Fisher Exact or the Mann Whitney test as appropriate. * overall detected microorganisms, includes repetitive detection in the same patient + multiplex PCR assay for respiratory syncytial virus (RSV) A/B, influenza A/B virus, adenovirus, coronaviruses 229E, HKU1, NL63 and OC43, human bocavirus, human metapneumovirus (hMPV), rhino/enterovirus and parainfluenzavirus 1-4 J o u r n a l P r e -p r o o f 20

Further information and requests for resources and reagents should be directed to the lead contacts, Philipp K. Buehler (philipp.buehler@usz.ch) or Silvio D. Brugger (silvio.brugger@usz.ch).

This study did not generate new unique materials.

The data and analysis scripts used in this study are available upon request to the Lead author.

No new code was generated.

The study was conducted as part of the MicrobiotaCOVID cohort study, a single-centre, prospective observational study conducted at the Institute of Intensive Care Medicine of the University Hospital Zurich (Zurich, Switzerland) registered at clinicaltrials.gov Exclusion criteria were patients or relatives denying informed consent and patients still being treated in the ICU when the study period ended.

The primary outcome was proportion of participants alive and off invasive mechanical ventilation at study day 28 days, i.e., ventilator-free days (VFDs) at 28 days 39 . Patients not on mechanical ventilation were excluded for the primary outcome analysis.

Secondary outcomes were length of hospital stay, ICU stay and duration of mechanical ventilation. Further outcomes included the association of pulmonary superinfection and bacteraemia, other virus co-infections, colonization with yeast, bacterial infections with multidrug resistance (MDR), and longitudinal laboratory inflammation parameters.

If the respiratory situation, as assessed by the ICU attending physician in charge, allowed bronchoscopy, BAL (10ml of saline) was collected by the ICU personnel upon ICU admission and during the later course of the disease. TBS was collected from each ventilated patient at least on day 0 (i.e. upon ICU admission), day 1, day 2, day 3, day 5 and henceforth every 5 days. If the clinical situation did not allow TBS collection, no sampling was performed. 

This study has been registered at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04410263, https://clinicaltrials.gov/ct2/show/NCT04410263). We followed the STROBE statement checklist in reports of cohort studies (https://www.strobestatement.org/index.php?id=available-checklists). J o u r n a l P r e -p r o o f

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV

Admitted to ICUs of the Lombardy Region

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

A Novel Coronavirus from Patients with Pneumonia in China

Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus

Early bacterial co-infection in ARDS related to COVID-19. Intensive care medicine

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Co-infections in people with COVID-19: a systematic review and meta-analysis

Hazardous mismatch between pulmonary pathogens and antibiotic treatments in COVID-19 patients

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. The Lancet Respiratory medicine

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine

Therapeutic and triage strategies for

novel coronavirus disease in fever clinics. The Lancet Respiratory medicine

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Co-infections: potentially lethal and unexplored in COVID-19

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

COVID-19, superinfections and antimicrobial development: What can we expect? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesthesia, critical care & pain medicine

Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA pediatrics

Co-infection with respiratory pathogens among COVID-2019 cases

Bacterial pneumonia as an influenza complication. Current opinion in infectious diseases

Middle East Respiratory Syndrome. The New England journal of medicine

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious diseases

Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern pathology : an official journal of the United States and Canadian Academy of Pathology

COVID-19 and the potential long-term impact on antimicrobial resistance

Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

COVID-19 associated pulmonary aspergillosis

Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Acute respiratory distress syndrome: the Berlin Definition

Bacterial colonization of handheld devices in a tertiary care setting: a hygiene intervention study

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Ventilator-associated pneumonia. American journal of respiratory and critical care medicine

Longitudinal laboratory inflammation parameters days 1-16. Depicted are median values and interquartile ranges